Clinical Trials

Find a Clinical Trial

Enrolling Trials

1-10  of  137
►
10323, Cancer Moonshot Biobank Research Protocol
Onitilo, Adedayo A
Miscellaneous Neoplasm
Adult
To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess the Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis
Kattamanchi, Siddhartha
Nephrology
Adult
This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Lehman, Elmer G
Ovaries, Uterus, Cervix - Ovaries
Adult
To compare the non inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations
Ottosen, Rebecca
(715) 393-1471
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor
Mosley, Anthony D
Neurology
Adult
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated social embarrassment. This study will assess how safe and effective BOTOX is in treating UL ET. Adverse events and change in disease activity will be evaluated. BOTOX is an investigational drug being developed for the treatment of UL ET. Participants are randomly assigned to 1 of the 4 groups, called treatment arms. Each group receives different treatment. There is 1 in 2 chance that participants will be assigned to placebo. Around 174 participants, aged 18 to 80 years with UL ET will be enrolled in approximately 40 sites in North America. Participants will receive BOTOX or placebo injections in Cycle 1 and Cycle 2. In Cycle 3, participants will receive unilateral or bilateral BOTOX injections. Each cycle is 12 weeks.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Brandt, Jon
Brain, Spinal Cord
Brain, Spinal Cord - Brain Primary
Child, Adult
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Brandt, Jon
Neuroblastoma
Child, Adult
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6- Valent OspA-Based Lyme Disease Vaccine in Healthy Participants =5 Years of Age
Haselby, Ray C
Infectious Disease
Adult, Child
The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 18,000 healthy participants 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence.
Freeman, Sandra K
(715) 387-9059
Johnson, Megan
(715) 389-4035
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Meilahn, Jill R
Nephrology
Adult, Child
The protocol describes a randomized, double-blind, placebo-controlled trial with 5 independent sub-studies of setmelanotide in patients with obesity and at least one of 6 specific gene defects in the Melanocortin-4 Receptor pathway: POMC or PCSK1 (Sub-study 035a); LEPR (Sub-study 035b); SRC1 (Sub-study 035c); SH2B1 (Sub-study 035d); PCSK1 N221D (Sub-study 035e). These 5 sub-studies have high degree of similarities. The objectives and endpoints are identical for all 5 sub-studies.
Freeman, Sandra K
(715) 387-9059
Gault, Tammy
(715) 387-5673
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Onitilo, Adedayo A
Lung - Lung
Adult
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Gokalp Yasar, Demet
Melanoma
Adult
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476